Skip to main content
Top
Published in: BMC Nephrology 1/2017

Open Access 01-12-2017 | Research article

β-trace protein is highly removed during haemodialysis with high-flux and super high-flux membranes

Authors: Carlo Donadio, Danika Tognotti, Laura Caponi, Aldo Paolicchi

Published in: BMC Nephrology | Issue 1/2017

Login to get access

Abstract

Background

Serum β-trace protein (βTP, MW 23–29 kDa) is a marker of GFR impairment in renal patients. Recent papers propose to predict residual renal function (RRF) in maintenance haemodialysis (MHD) patients from serum concentrations of βTP and other small proteins, avoiding the collection of urine. Few data are available on the removal of βTP in patients treated with dialysis membranes with different flux characteristics. The aim of this study was to evaluate the effects of haemodialysis with low-flux, high-flux and super high-flux membranes on serum concentrations of ßTP in MHD patients with null RRF.

Methods

Serum ßTP concentrations were measured before and after the first dialysis of the week in 51 MDH patients treated by low-flux (n = 24), high-flux (n = 17), or super high-flux (n = 10) membranes. The removal of β2-microglobulin (β2M, MW 11.8), cystatin C (Cys, MW 13.3), urea and creatinine was also analyzed.

Results

Low-flux membranes did not remove βTP, β2M and Cys whose concentration increased at the end of dialysis. High-flux membrane removed more efficiently β2M and Cys than ßTP. Super high-flux membrane had the highest efficiency to remove ßTP: mean reduction ratio (RR) 53.4%, similar to β2M (59.5%), and Cys (62.0%).

Conclusions

In conclusion, the plasma clearance of small proteins and particularly of βTP is dependent from the permeability of the dialysis membranes Therefore, the reliability of the formulas proposed to predict RRF from serum βTP and other LMWP may be affected by the different permeability of the dialysis membranes.
Literature
1.
go back to reference Stel VS, Dekker FW, Ansell D, et al. Residual renal function at the start of dialysis and clinical outcomes. Nephrol Dial Transplant. 2009;24:3175–82.CrossRefPubMed Stel VS, Dekker FW, Ansell D, et al. Residual renal function at the start of dialysis and clinical outcomes. Nephrol Dial Transplant. 2009;24:3175–82.CrossRefPubMed
2.
go back to reference Vilar E, Wellsted D, Chandna SM, Greenwood RN, Farrington K. Residual renal function improves outcome in incremental haemodialysis despite reduced dialysis dose. Nephrol Dial Transplant. 2009;24:2502–10.CrossRefPubMed Vilar E, Wellsted D, Chandna SM, Greenwood RN, Farrington K. Residual renal function improves outcome in incremental haemodialysis despite reduced dialysis dose. Nephrol Dial Transplant. 2009;24:2502–10.CrossRefPubMed
3.
go back to reference van der Wal WM, Noordzij M, Dekker FW, et al. Full loss of residual renal function causes higher mortality in dialysis patients; findings from a marginal structural model. Nephrol Dial Transplant. 2011;26:2978–83.CrossRefPubMed van der Wal WM, Noordzij M, Dekker FW, et al. Full loss of residual renal function causes higher mortality in dialysis patients; findings from a marginal structural model. Nephrol Dial Transplant. 2011;26:2978–83.CrossRefPubMed
4.
go back to reference Wong J, Vilar E, Davenport A, Farrington K. Incremental haemodialysis. Nephrol Dial Transplant. 2015;30:1639–48.CrossRefPubMed Wong J, Vilar E, Davenport A, Farrington K. Incremental haemodialysis. Nephrol Dial Transplant. 2015;30:1639–48.CrossRefPubMed
5.
go back to reference Hemodialysis Adequacy 2006 Work Group. Clinical practice guidelines for hemodialysis adequacy, update 2006. Am J Kidney Dis. 2006;48 suppl 1:S2–90. Hemodialysis Adequacy 2006 Work Group. Clinical practice guidelines for hemodialysis adequacy, update 2006. Am J Kidney Dis. 2006;48 suppl 1:S2–90.
6.
go back to reference European Best Practice Guidelines. Section I. Measurement of renal function, when to refer and when to start dialysis. Nephrol Dial Transplant. 2002;17 suppl 7:7–15. European Best Practice Guidelines. Section I. Measurement of renal function, when to refer and when to start dialysis. Nephrol Dial Transplant. 2002;17 suppl 7:7–15.
7.
go back to reference Hoffmann A, Conradt HS, Gross G, et al. Purification and chemical characterization of beta-trace protein from human cerebrospinal fluid: its identification as prostaglandin D synthase. J Neurochem. 1993;61:451–6.CrossRefPubMed Hoffmann A, Conradt HS, Gross G, et al. Purification and chemical characterization of beta-trace protein from human cerebrospinal fluid: its identification as prostaglandin D synthase. J Neurochem. 1993;61:451–6.CrossRefPubMed
8.
go back to reference Hoffmann A, Nimtz M, Conradt HS. Molecular characterization of beta-trace protein in human serum and urine: a potential diagnostic marker for renal disease. Glycobiology. 1997;7:499–506.CrossRefPubMed Hoffmann A, Nimtz M, Conradt HS. Molecular characterization of beta-trace protein in human serum and urine: a potential diagnostic marker for renal disease. Glycobiology. 1997;7:499–506.CrossRefPubMed
9.
go back to reference Whitsed H, Penny R. Beta trace protein. Purification and urinary excretion studies in selected diseases. Clin Chim Acta. 1974;50:111–8.CrossRefPubMed Whitsed H, Penny R. Beta trace protein. Purification and urinary excretion studies in selected diseases. Clin Chim Acta. 1974;50:111–8.CrossRefPubMed
10.
go back to reference Nagata N, Fujimori K, Okazaki I, et al. De novo synthesis, uptake and proteolytic processing of lipocalin-type prostaglandin D synthase, beta-trace, in the kidneys. FEBSJ. 2009;276:7146–58.CrossRef Nagata N, Fujimori K, Okazaki I, et al. De novo synthesis, uptake and proteolytic processing of lipocalin-type prostaglandin D synthase, beta-trace, in the kidneys. FEBSJ. 2009;276:7146–58.CrossRef
11.
go back to reference Priem F, Althaus H, Birnbaum M, et al. Beta-Trace protein in serum: a new marker of glomerular filtration rate in the creatinine-blind range. Clin Chem. 1999;45:567–8.PubMed Priem F, Althaus H, Birnbaum M, et al. Beta-Trace protein in serum: a new marker of glomerular filtration rate in the creatinine-blind range. Clin Chem. 1999;45:567–8.PubMed
12.
go back to reference Priem F, Althaus H, Jung K, et al. Beta-Trace protein is not better than cystatin C as an indicator of reduced glomerular filtration rate. Clin Chem. 2001;47:2181.PubMed Priem F, Althaus H, Jung K, et al. Beta-Trace protein is not better than cystatin C as an indicator of reduced glomerular filtration rate. Clin Chem. 2001;47:2181.PubMed
13.
go back to reference Filler G, Priem F, Lepage N, et al. Beta-Trace protein, cystatin C, beta2-microglobulin, and creatinine compared for detecting impaired glomerular filtration rate in children. Clin Chem. 2002;48:729–36.PubMed Filler G, Priem F, Lepage N, et al. Beta-Trace protein, cystatin C, beta2-microglobulin, and creatinine compared for detecting impaired glomerular filtration rate in children. Clin Chem. 2002;48:729–36.PubMed
14.
go back to reference Donadio C, Lucchesi A, Ardini M, et al. Serum levels of beta-trace protein and glomerular filtration rate—preliminary results. J Pharm Biomed Anal. 2003;32:1099–104.CrossRefPubMed Donadio C, Lucchesi A, Ardini M, et al. Serum levels of beta-trace protein and glomerular filtration rate—preliminary results. J Pharm Biomed Anal. 2003;32:1099–104.CrossRefPubMed
15.
go back to reference Donadio C. Serum and urinary markers of early impairment of GFR in chronic kidney disease patients: diagnostic accuracy of urinary β-trace protein. Am J Physiol Renal Physiol. 2010;299:F1407–23.CrossRefPubMed Donadio C. Serum and urinary markers of early impairment of GFR in chronic kidney disease patients: diagnostic accuracy of urinary β-trace protein. Am J Physiol Renal Physiol. 2010;299:F1407–23.CrossRefPubMed
16.
go back to reference Wong J, Sridharan S, Berdeprado J, et al. Predicting residual kidney function in hemodialysis patients using serum β-trace protein and β2-microglobulin. Kidney Int. 2016;89:1090–8.CrossRefPubMed Wong J, Sridharan S, Berdeprado J, et al. Predicting residual kidney function in hemodialysis patients using serum β-trace protein and β2-microglobulin. Kidney Int. 2016;89:1090–8.CrossRefPubMed
17.
go back to reference Shafi T, Michels WM, Levey AS, et al. Estimating residual kidney function in dialysis patients without urine collection. Kidney Int. 2016;89:1099–110.CrossRefPubMed Shafi T, Michels WM, Levey AS, et al. Estimating residual kidney function in dialysis patients without urine collection. Kidney Int. 2016;89:1099–110.CrossRefPubMed
18.
go back to reference Davenport A. Measuring residual renal function in dialysis patients: can we dispense with 24-hour urine collections? Kidney Int. 2016;89:978–80.CrossRefPubMed Davenport A. Measuring residual renal function in dialysis patients: can we dispense with 24-hour urine collections? Kidney Int. 2016;89:978–80.CrossRefPubMed
19.
go back to reference Brown PH, Kalra PA, Turney JH, Cooper EH. Serum low-molecular-weight proteins in haemodialysis patients: effect of residual renal function. Nephrol Dial Transplant. 1988;3:169–73.PubMed Brown PH, Kalra PA, Turney JH, Cooper EH. Serum low-molecular-weight proteins in haemodialysis patients: effect of residual renal function. Nephrol Dial Transplant. 1988;3:169–73.PubMed
20.
go back to reference Kabanda A, Jadoul M, Pochet JM, Lauwerys R, van Ypersele de Strihou C, Bernard A. Determinants of the serum concentrations of low molecular weight proteins in patients on maintenance hemodialysis. Kidney Int. 1994;45:1689–96.CrossRefPubMed Kabanda A, Jadoul M, Pochet JM, Lauwerys R, van Ypersele de Strihou C, Bernard A. Determinants of the serum concentrations of low molecular weight proteins in patients on maintenance hemodialysis. Kidney Int. 1994;45:1689–96.CrossRefPubMed
21.
go back to reference Lindstrom V, Grubb A, Alquist Hegbrant M, et al. Different elimination patterns of beta-trace protein, beta2-microglobulin and cystatin C in haemodialysis, haemodiafiltration and haemofiltration. Scand J Clin Lab Invest. 2008;68:685–91.CrossRefPubMed Lindstrom V, Grubb A, Alquist Hegbrant M, et al. Different elimination patterns of beta-trace protein, beta2-microglobulin and cystatin C in haemodialysis, haemodiafiltration and haemofiltration. Scand J Clin Lab Invest. 2008;68:685–91.CrossRefPubMed
22.
go back to reference Gerhardt T, Poge U, Stoffel-Wagner B, et al. Serum levels of beta-trace protein and its association to diuresis in haemodialysis patients. Nephrol Dial Transplant. 2008;23:309–14.CrossRefPubMed Gerhardt T, Poge U, Stoffel-Wagner B, et al. Serum levels of beta-trace protein and its association to diuresis in haemodialysis patients. Nephrol Dial Transplant. 2008;23:309–14.CrossRefPubMed
23.
go back to reference Hoek FJ, Korevaar JC, Dekker FW, et al. Estimation of residual glomerular filtration rate in dialysis patients from the plasma cystatin C level. Nephrol Dial Transplant. 2007;22:1633–8.CrossRefPubMed Hoek FJ, Korevaar JC, Dekker FW, et al. Estimation of residual glomerular filtration rate in dialysis patients from the plasma cystatin C level. Nephrol Dial Transplant. 2007;22:1633–8.CrossRefPubMed
24.
go back to reference Zhong H, Zhang W, Qin M, Gou Z, Feng P. Validation of cystatin C–based equations for evaluating residual renal function in patients on continuous ambulatory peritoneal dialysis. Nephrol Dial Transplant. 2016. doi:10.1093/ndt/gfw096. Zhong H, Zhang W, Qin M, Gou Z, Feng P. Validation of cystatin C–based equations for evaluating residual renal function in patients on continuous ambulatory peritoneal dialysis. Nephrol Dial Transplant. 2016. doi:10.​1093/​ndt/​gfw096.
Metadata
Title
β-trace protein is highly removed during haemodialysis with high-flux and super high-flux membranes
Authors
Carlo Donadio
Danika Tognotti
Laura Caponi
Aldo Paolicchi
Publication date
01-12-2017
Publisher
BioMed Central
Published in
BMC Nephrology / Issue 1/2017
Electronic ISSN: 1471-2369
DOI
https://doi.org/10.1186/s12882-017-0489-6

Other articles of this Issue 1/2017

BMC Nephrology 1/2017 Go to the issue